Product logins

Find logins to all Clarivate products below.


Contrast Agents and Radiopharmaceuticals | US | 2015 | Market Analysis

The US market for contrast agents and radiopharmaceuticals will be limited by reimbursement restrictions and lower dosing; nonetheless, growth in the large radiopharmaceutical market and favorable demographics will result in a modest expansion of the market through 2023.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals across a 10-year period.

Related Medtech Insights Reports

Report
Contrast Agents and Radiopharmaceuticals – Market Insights – United States
The US contrast agents and radiopharmaceutical market will see moderate growth over the forecast period. Market growth will be driven by rising PET and MRI procedure volumes, and the expanding use…
Report
Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2024
The US contrast agents and radiopharmaceutical market was severely impacted by the COVID-19 pandemic in 2020, but has already shown significant recovery in 2021 and 2022; however, it continues to…
Report
Contrast Agents and Radiopharmaceuticals – Market Insights – Europe
The COVID-19 pandemic negatively impacted the European contrast agents and radiopharmaceutical market in 2020. Following the recovery, growth in the European market will be supported by the…
Report
Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2022
The global COVID-19 pandemic has negatively impacted the US contrast agents and radiopharmaceutical market to some extent. During the initial onset of the pandemic and at periods of high local…
Report
Contrast Agents and Radiopharmaceuticals | Market Insights | Europe | 2022
Although demand for contrast-enhanced CT for the diagnosis and monitoring of COVID-19 cases has slightly mitigated the impact of the global pandemic on the European contrast agent and…